Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 521.4 CHF -0.04% Market Closed
Market Cap: 35.9B CHF
Have any thoughts about
Lonza Group AG?
Write Note

Lonza Group AG
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lonza Group AG
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Lonza Group AG
SIX:LONN
Total Liabilities
CHf7.4B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
5%
Bachem Holding AG
SIX:BANB
Total Liabilities
CHf415m
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
17%
Siegfried Holding AG
SIX:SFZN
Total Liabilities
CHf971m
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Total Liabilities
CHf710.2m
CAGR 3-Years
26%
CAGR 5-Years
20%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Total Liabilities
€307.9m
CAGR 3-Years
16%
CAGR 5-Years
18%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Total Liabilities
CHf204.2m
CAGR 3-Years
-2%
CAGR 5-Years
139%
CAGR 10-Years
N/A
No Stocks Found

Lonza Group AG
Glance View

Market Cap
37.6B CHF
Industry
Life Sciences Tools & Services

Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biologics, Lonza stands out for its extensive technological capabilities and state-of-the-art facilities, positioning itself at the forefront of an industry that is rapidly transforming healthcare. For investors seeking to understand Lonza's value proposition, it’s essential to appreciate the company's robust financial performance and strategic growth initiatives. Lonza has consistently demonstrated strong revenue growth, driven by its diversified portfolio and a commitment to research and development. The company has made significant investments in expanding its global manufacturing footprint, notably through the integration of advanced technology for efficient production processes. Furthermore, Lonza's strategic collaborations with major pharmaceutical enterprises in cell and gene therapies highlight its potential for sustained growth. As the world increasingly emphasizes innovation in the healthcare sector, Lonza Group AG remains well-poised to capitalize on emerging opportunities, making it an attractive prospect for investors looking to tap into the growing life sciences market.

LONN Intrinsic Value
613.89 CHF
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Lonza Group AG's Total Liabilities?
Total Liabilities
7.4B CHF

Based on the financial report for Jun 30, 2024, Lonza Group AG's Total Liabilities amounts to 7.4B CHF.

What is Lonza Group AG's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
5%

Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Lonza Group AG have been -2% over the past three years , and 5% over the past ten years .

Back to Top